Craniopharyngioma is considered to arise from Rathke pouch epithelium, per WHO-adapted Orphanet-linked definitions. No causative germline genes are recorded in the known_genes field for this disease. No Mendelian inheritance pattern is catalogued. The condition presents typically as sporadic in origin.

Diagnostic classification distinguishes two clinicopathological subtypes: adamantinomatous and papillary craniopharyngioma. Tumor size is a recognized prognostic factor per the WHO-adapted Orphanet definition, with lesions exceeding 5 cm in diameter associated with markedly worse outcomes. No specific diagnostic laboratory criteria are enumerated in the current packet.

No FDA-approved pharmacological treatments for craniopharyngioma are catalogued in the current packet. Active and recruiting clinical trials listed in ClinicalTrials.gov document investigations of surgical resection extent, proton radiotherapy approaches, targeted molecular agents for mutation-defined tumor subtypes, and biologic interventions for the adamantinomatous subtype. Both pediatric and adult disease cohorts are represented in the trial registry.

Per the WHO-adapted definition catalogued in Orphanet sources, the extent of surgical resection is identified as the most significant factor associated with disease recurrence. Lesions exceeding 5 cm in diameter carry a markedly worse prognosis. A patient registry is maintained by the Raymond A. Wood Foundation, catalogued in the packet's patient organization field.

Multiple clinical trials catalogued in ClinicalTrials.gov address craniopharyngioma, including Phase 2 studies investigating both the adamantinomatous and papillary subtypes, as well as imaging-focused and observational research. Kisho's publication pipeline has classified 69 items in this disease area, the majority of which are review articles and meta-analyses.